Meeting
2018 Gastrointestinal Cancers Symposium
Volume reduction rate of the primary tumor as an objective clinical measure to evaluate efficacy of neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Authors
Shinsuke Nagasawa
Kanagawa Cancer Center, Yokohama, Japan
Shinsuke Nagasawa , Takashi Ogata , Kentaro Hara , Hiroaki Osakabe , Masato Nakazono , Yuta Kumazu , Tsutomu Hayashi , Takanobu Yamada , Yasushi Rino , Munetaka Masuda , Takaki Yoshikawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 42)
DOI
10.1200/JCO.2018.36.4_suppl.42
Abstract #
42
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase II trial of perioperative chemotherapy of esophageal cancer: PIECE trial.
First Author: Motoo Nomura
Poster
2015 Gastrointestinal Cancers Symposium
Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A).
First Author: Motoo Nomura
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.
First Author: Yuri Yoshinami
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose